Gianluca Ingrosso - Publications

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making.

Journal: Expert review of clinical pharmacology

Published: May 19, 2026

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: February 17, 2026

Ultra-hypofractionated whole breast irradiation in early-stage breast cancer: an Italian multi-centre observational study.

Journal: International journal of radiation oncology, biology, physics

Published: January 17, 2026

Impact of BRCA in patients undergoing abiraterone ± stereotactic body radiotherapy: the ARTO trial.

Journal: BJU international

Published: December 15, 2025

Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE).

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 16, 2025

Recent Advances in Androgen Receptor Pathway Inhibitors for Castration-Sensitive Prostate Cancer.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: September 08, 2025

Ablative radiotherapy for polymetastatic disease: a new kid on the block.

Journal: Expert review of anticancer therapy

Published: August 01, 2025

The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology.

Journal: Journal of personalized medicine

Published: July 04, 2025

Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer.

Journal: Expert review of anticancer therapy

Published: May 21, 2025

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).

Journal: Prostate cancer and prostatic diseases

Published: November 28, 2024

Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study.

Journal: Prostate cancer and prostatic diseases

Published: November 12, 2024

Prostate MRI: bridging radiology and radiation oncology for precision radiation therapy.

Journal: European radiology

Published: September 15, 2024